SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/